TY - JOUR
T1 - Calcineurin Inhibitors
T2 - Pharmacologic Mechanisms Impacting Both Insulin Resistance and Insulin Secretion Leading to Glucose Dysregulation and Diabetes Mellitus
AU - Chakkera, H. A.
AU - Kudva, Y.
AU - Kaplan, B.
N1 - Publisher Copyright:
© 2016 American Society for Clinical Pharmacology and Therapeutics
PY - 2017/1/1
Y1 - 2017/1/1
N2 - Calcineurin inhibitors (CNIs), including tacrolimus and cyclosporine, are immune-modulating agents used in autoimmune disorders, glomerulonephritides, and after transplantation. CNIs are implicated as diabetogenic drugs but the mechanism is not clearly elucidated. Calcineurin is a cytosolic-phosphatase critical for T-lymphocyte activation. Calcineurin is widely distributed in different tissues responsible for glucose-regulation including pancreas, liver, skeletal muscle, adipocytes, brain, and gut. We describe the pharmacologic effects of CNIs in different tissues and impact on glucose regulation.
AB - Calcineurin inhibitors (CNIs), including tacrolimus and cyclosporine, are immune-modulating agents used in autoimmune disorders, glomerulonephritides, and after transplantation. CNIs are implicated as diabetogenic drugs but the mechanism is not clearly elucidated. Calcineurin is a cytosolic-phosphatase critical for T-lymphocyte activation. Calcineurin is widely distributed in different tissues responsible for glucose-regulation including pancreas, liver, skeletal muscle, adipocytes, brain, and gut. We describe the pharmacologic effects of CNIs in different tissues and impact on glucose regulation.
UR - http://www.scopus.com/inward/record.url?scp=85006137995&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85006137995&partnerID=8YFLogxK
U2 - 10.1002/cpt.546
DO - 10.1002/cpt.546
M3 - Review article
C2 - 27804122
AN - SCOPUS:85006137995
SN - 0009-9236
VL - 101
SP - 114
EP - 120
JO - Clinical pharmacology and therapeutics
JF - Clinical pharmacology and therapeutics
IS - 1
ER -